Ticker Details
Penumbra, Inc. Penumbra Inc designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and vascular conditions that can be treated through thrombectomy and embolization procedures.
IPO Date:	September 18, 2015
Sector:	Healthcare
Industry:	Medical Devices
Market Cap:	$12.93B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$3.04 | 1.75%
Avg Daily Range (30 D):	$1.12 | 0.33%
Avg Daily Range (90 D):	$2.39 | 0.76%

Institutional Daily Volume
Avg Daily Volume:	.31M
Avg Daily Volume (30 D):	.51M
Avg Daily Volume (90 D):	.72M

Trade Size
Avg Trade Size (Sh.):	47
Avg Trade Size (Sh.) (30 D):	27
Avg Trade Size (Sh.) (90 D):	32

Institutional Trades
Total Institutional Trades:	4,054
Avg Institutional Trade:	$6.73M
Avg Institutional Trade (30 D):	$19.6M
Avg Institutional Trade (90 D):	$17.53M
Avg Institutional Trade Volume:	.03M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$8.79M
Avg Closing Trade (30 D):	$30.16M
Avg Closing Trade (90 D):	$31.21M
Avg Closing Volume:	40.83K

News

Mar 5, 2026 @ 6:15 PM 3 Reasons Boston Scientific Stock Could Quietly 5X... Source: Eric Volkman

Feb 2, 2026 @ 10:49 PM Halper Sadeh LLC Reminds Shareholders of RAPT, PEN... Source: Halper Sadeh Llc

Jan 28, 2026 @ 7:23 PM $HAREHOLDER ALERT: The M&A Class Action Firm Is In... Source: Prnewswire

Jan 21, 2026 @ 9:52 PM Halper Sadeh LLC Encourages PEN, EXAS, DBRG, FFIC ... Source: Halper Sadeh Llc

Jan 21, 2026 @ 5:30 PM Boston Scientific Advises Removal Of Certain AXIOS... Source: Vandana Singh

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$4.57	$1.21	$4.57
Diluted EPS	$4.52	$1.2	$4.52
Revenue	$1.4B	$385.39M	$1.4B
Gross Profit	$942.44M	$262.13M	$942.44M
Net Income / Loss	$177.69M	$47.34M	$177.69M
Operating Income / Loss	$189.25M	$59.23M	$189.25M
Cost of Revenue	$461.23M	$123.26M	$461.23M
Net Cash Flow	$-137.51M	$-134.13M	$-137.51M
PE Ratio	72.96